Aptar Pharma Transfers Advanced Preservative-Free Production Line to Argentina, Expanding Local Drug Delivery Manufacturing
Aptar Pharma, a global provider of drug delivery, dosing, protection technologies and related services, has announced the successful transfer and commissioning of its Aptar Pharma Preservative Free (APF) production line at its manufacturing facility in Berazategui, Argentina. The investment is designed to bring Aptar Pharma’s Advanced Preservative Free pump technology closer to pharmaceutical and consumer healthcare customers throughout Latin America while strengthening the company’s regional manufacturing capabilities.
The newly commissioned production line represents another step in Aptar Pharma’s broader strategy of developing manufacturing capabilities closer to the markets and customers it serves. By establishing APF production locally in Argentina, the company expects to improve supply agility, support shorter lead times and enhance the availability of advanced drug delivery technologies for customers across the region.
The initiative also reflects the growing importance of localized manufacturing within the pharmaceutical supply chain, particularly as drug developers and healthcare companies seek greater resilience, flexibility and responsiveness in the production and distribution of medicines and drug delivery systems.
Berazategui Facility Serves as Aptar Pharma’s Latin American Manufacturing Hub
Aptar Pharma’s Berazategui facility is located south of Buenos Aires and serves as an important industrial hub for the company’s operations in Latin America. The site supplies customers across 15 countries and provides manufacturing capabilities for both consumer healthcare and prescription pharmaceutical markets.
The facility includes approximately 2,500 square meters dedicated to manufacturing drug delivery systems. Through this infrastructure, Aptar Pharma supports customers requiring technologies for pharmaceutical products as well as consumer healthcare applications.
The commissioning of the APF production line adds an important capability to this regional manufacturing footprint. Instead of relying solely on production from other global locations, customers in Latin America can benefit from access to APF technology through Aptar Pharma’s local manufacturing infrastructure.
This approach is intended to make the company’s supply chain more responsive to regional demand while supporting customers as they develop and commercialize products that require advanced dispensing technologies.
The investment also reinforces Aptar Pharma’s longstanding presence in the Latin American healthcare market. The company has worked with customers in the region for more than two decades, providing drug delivery solutions intended to support pharmaceutical and healthcare products used by millions of patients.
Advanced Preservative-Free Pump Technology
At the center of the investment is Aptar Pharma’s Advanced Preservative Free, or APF, pump. The technology is a multidose spray dispensing system designed for preservative-free nasal formulations.
Preservative-free drug delivery systems have become increasingly important as pharmaceutical companies develop formulations and products designed to meet specific patient and product requirements. Aptar Pharma’s APF technology is designed to help maintain microbiological integrity through mechanical means, providing a dispensing approach that does not depend on conventional preservatives in the formulation.
The technology can therefore support customers developing differentiated nasal healthcare products where a preservative-free formulation is desirable.
For pharmaceutical companies, the availability of suitable drug delivery technology can be an important part of product development. The delivery system must work with the formulation, provide consistent dosing and help maintain product integrity throughout its intended use.
A multidose nasal spray system also needs to address microbiological considerations because the container may be used repeatedly over time. Aptar Pharma’s APF technology is designed to address these requirements through its mechanical preservation approach.
By transferring production of the APF system to Argentina, Aptar Pharma is bringing this technology closer to customers in Latin America and strengthening its ability to support regional product development and supply requirements.
Investment Supports Local-for-Local Manufacturing Strategy
The APF line transfer forms part of Aptar Pharma’s broader global expansion program and its local-for-local manufacturing strategy.
Under this approach, Aptar Pharma is investing in manufacturing capabilities across key geographic markets to bring technologies closer to customers while increasing capacity and supply-chain flexibility.
The company has made recent and ongoing investments in several locations around the world, including Congers, New York; Suzhou, China; and Mumbai, India. These investments are intended to increase manufacturing capabilities, strengthen innovation and support customers in major pharmaceutical and healthcare markets.
The Argentine investment adds another regional component to this global network.
Rather than treating manufacturing as a centralized global activity, the local-for-local model enables Aptar Pharma to develop capabilities in markets where demand is growing and where customers can benefit from closer access to production and technical resources.
For customers in Latin America, the APF line in Berazategui is expected to contribute to this strategy by improving regional supply capabilities for the preservative-free nasal spray technology.
Greater Supply Agility for Latin American Customers
Supply-chain resilience has become an increasingly important consideration for pharmaceutical companies and their technology partners. Delays in manufacturing, transportation or international logistics can affect product development schedules and commercial supply.
Local manufacturing can help reduce some of these logistical challenges by placing production capacity closer to customers.
Aptar Pharma said the APF production line transfer is expected to strengthen regional supply agility, reduce lead times and enhance product availability for customers across Latin America.
The benefits are particularly relevant for pharmaceutical companies developing products for regional markets, where access to nearby manufacturing and supply infrastructure can provide greater flexibility.
The new capability can also allow Aptar Pharma to respond more effectively to changes in regional demand. Having production capabilities within the market can provide customers with a closer manufacturing resource while complementing Aptar Pharma’s broader global network.
Julie Pradeilles, President, Consumer Healthcare, Aptar Pharma, said the transfer reflects the company’s continued investment in bringing established technologies closer to customers and patients worldwide.
According to Pradeilles, establishing APF production in Argentina strengthens Aptar Pharma’s local-for-local manufacturing approach while supporting greater agility for customers in Latin America. She described the initiative as an example of how the company’s global manufacturing footprint can be used to expand access to innovative drug delivery solutions in markets where they are needed.
Addressing Healthcare Access Challenges in Latin America
The investment also comes against the backdrop of continuing challenges associated with access to medicines and healthcare technologies across Latin America.
Pharmaceutical companies operating in the region can face complex supply and distribution requirements across multiple countries and markets. Manufacturing and technology capabilities located closer to customers can help create a more responsive regional supply network.
Marcos Garcia, Vice President, Aptar Pharma Latin America, highlighted access to medicines as an important challenge for the pharmaceutical industry in the region.
Garcia said that bringing technology and manufacturing capabilities closer to Latin American customers can allow Aptar Pharma to provide shorter lead times, improve product availability and deliver solutions that can help expand the reach of healthcare.
The Berazategui APF production line is therefore positioned not only as a manufacturing investment but also as part of Aptar Pharma’s wider effort to support the pharmaceutical ecosystem in Latin America.
By combining global technology development with regional manufacturing, the company aims to offer customers the advantages of an international drug delivery partner while maintaining local capabilities.
Supporting Pharmaceutical and Consumer Healthcare Markets
Aptar Pharma’s Berazategui facility supports both prescription pharmaceutical and consumer healthcare customers. This dual-market capability gives the facility a broad role within Aptar Pharma’s Latin American operations.
Drug delivery systems are increasingly important across both markets as pharmaceutical companies and consumer healthcare brands seek delivery technologies that can improve product performance, usability and differentiation.
For prescription medicines, delivery systems can form an integral part of a pharmaceutical product and its patient-use experience. For consumer healthcare products, dispensing performance, convenience and product protection can similarly influence product selection and use.
Aptar Pharma’s APF pump is specifically focused on nasal formulations, an area in which spray delivery technology can play an important role in providing controlled and convenient administration.
The local availability of the APF system can therefore provide Latin American customers with a closer source of advanced dispensing technology as they develop or expand nasal healthcare products.
Part of Aptar Pharma’s Broader Global Expansion
The Argentina investment is one element of a wider expansion program that spans multiple regions.
Aptar Pharma’s investments in Congers, New York, Suzhou, China, and Mumbai, India, demonstrate the company’s efforts to increase manufacturing capacity across major markets. Together with the Berazategui initiative, these investments are designed to create a more geographically distributed manufacturing network.
Such a network can provide strategic advantages by allowing the company to support customers through regional production while maintaining access to its broader global capabilities.
The strategy also reflects the changing expectations of pharmaceutical and healthcare customers, who increasingly seek supply partners capable of combining technology, manufacturing expertise and regional responsiveness.
For Aptar Pharma, expanding local manufacturing capacity provides a way to align its global drug delivery portfolio with the specific supply-chain needs of individual markets.
Strengthening Regional Drug Delivery Infrastructure
The successful commissioning of the APF production line marks a significant development for Aptar Pharma’s Latin American manufacturing operations.
With approximately 2,500 square meters dedicated to drug delivery systems at its Berazategui facility and a customer base spanning 15 countries, the site provides a platform for supporting pharmaceutical and consumer healthcare markets throughout the region.
The addition of APF production expands the range of advanced technologies that can be supplied from the region and reinforces Aptar Pharma’s long-term commitment to Latin American customers.
The company’s focus on preservative-free nasal delivery also aligns with the continuing development of differentiated pharmaceutical formulations and delivery systems. Through the APF pump, Aptar Pharma provides a multidose spray solution designed to maintain microbiological integrity through mechanical means.
As pharmaceutical companies continue to seek drug delivery technologies that can support innovative formulations and improve supply-chain flexibility, local manufacturing may become increasingly important.
For Aptar Pharma, the Argentina investment combines these priorities by bringing an established technology closer to customers while strengthening the company’s regional infrastructure.
The commissioning of the APF line ultimately underscores Aptar Pharma’s broader strategy of pairing global drug delivery expertise with local manufacturing capabilities. Through its local-for-local approach, the company aims to improve responsiveness, strengthen supply availability and help customers across Latin America gain closer access to advanced drug delivery technologies.
With the Berazategui facility now producing the APF system, Aptar Pharma is further expanding its ability to serve pharmaceutical and consumer healthcare customers from within the region while continuing its broader global manufacturing expansion program.
About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.